ENTA

Enanta Pharmaceuticals (ENTA)

About Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Details

Daily high
$6.31
Daily low
$5.72
Price at open
$5.84
52 Week High
$17.80
52 Week Low
$5.70
Market cap
133.1M
Dividend yield
0.00%
Volume
655,721
Avg. volume
512,465
P/E ratio
-1.14

Enanta Pharmaceuticals News

Details

Daily high
$6.31
Daily low
$5.72
Price at open
$5.84
52 Week High
$17.80
52 Week Low
$5.70
Market cap
133.1M
Dividend yield
0.00%
Volume
655,721
Avg. volume
512,465
P/E ratio
-1.14